Generics Bulletin Originals
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
The biggest loss of exclusivity in pharmaceutical history is set to steal headlines in the first month of 2023, as Teva begins a new year with a new CEO.
In a busy final month of the year, key legal action will be heard in both the US and Europe, while the Medicines Patent Pool will hear from applicants for a milestone voluntary licensing agreement covering Novartis’ nilotinib.
European litigation, potential US generic launches and new CEOs are among the headlines in November – amid the ninth annual Global Generics & Biosimilars Awards, in Frankfurt.
A busy October will include planned biosimilar launches and key appointments for the off-patent sector.
With Dr Reddy’s organization now spanning a range of innovative interests and CDMO activities as well as the firm’s traditional small-molecule generics and burgeoning biosimilars businesses, CEO Erez Israeli talked to Generics Bulletin about how these various areas were complementary thanks to the Indian giant’s ‘two-horizon’ approach.
Following Fresenius Kabi’s approval in mid-December for the eighth and latest biosimilar Humira (adalimumab) product, the company’s senior vice president for biosimilars in the US spoke to Generics Bulletin about how it can stand out from the pack and why it is confident that it can succeed.
The head of biosimilars for Biogen in the UK & Ireland, Jim Porter, sat down with Generics Bulletin to discuss “system challenges and changes that we’re seeing within the UK’s NHS,” as well as Biogen’s own position in what it says is a very important market for the company.
Medicines for Europe is calling on the EU to recognize value-added medicines as its own separate group in its pharmaceutical legislation.
Average trade prices for multiple products more than doubled in December in the UK, according to the latest figures from market researcher WaveData.
Multiple treble-digit price rises were seen for UK generics in November as a lengthy list of price concessions was issued by the Department of Health and Social Care.
Having led the fastest-rising average trade prices in the UK in August, aripiprazole once again topped our table of Biggest Risers in October, based on the latest figures from market researcher WaveData – but this time it was the oral solution presentation of the product that saw a spike.
September brought triple-digit percentage increases in the average trade price of multiple UK generics, according to the latest figures from WaveData.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.